Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: Analgesic efficacy, pharmacokinetics and tolerability

British Journal of Clinical Pharmacology

Volumn 81, Issue 3, 2016, Pages 525-537

  De Vries, Marjan ^a   Van Rijckevorsel, Dagmar C M ^a   Vissers, Kris C P ^a,b   Wilder Smith, Oliver H G ^a   Van Goor, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

chronic pain; chronic pancreatitis; delta 9 tetrahydrocannabinol; dronabinol; THC

Indexed keywords

DIAZEPAM; DRONABINOL; ANALGESIC AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9;

ABDOMINAL PAIN; ADULT; ANALGESIC ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CHRONIC PAIN; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEMALE; HEART RATE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NAUSEA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE; XEROSTOMIA; AGED; BLOOD; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GENOTYPE; PAIN MEASUREMENT; PANCREATITIS, CHRONIC;

ABDOMINAL PAIN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; CHRONIC PAIN; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PANCREATITIS, CHRONIC;

EID: 84959431900     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12811     Document Type: Article

References (60)

1. Sarles H,. Definitions and classifications of pancreatitis. Pancreas 1991; 6: 470-4.
2. Andren-Sandberg A, Hoem D, Gislason H,. Pain management in chronic pancreatitis. Eur J Gastroenterol Hepatol 2002; 14: 957-70.
3. Warshaw ALBP, Fernandez-Del Castillo C,. American gastroenterological association medical position statement:treatment of pain in chronic pancreatitis. Gastroenterology 1998; 115: 763-4.
4. Fishbain DA, Cole B, Lewis JE, Gao J, Rosomoff RS,. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med 2009; 10: 829-39.
5. Tompkins DA, Campbell CM,. Opioid-Induced Hyperalgesia: Clinically Relevant or Extraneous Research Phenomenon? Curr Pain Headache Rep 2011; 15: 129-36.
6. Chauhan S, Forsmark CE,. Pain management in chronic pancreatitis: A treatment algorithm. Best Pract Res Clin Gastroenterol 2010; 24: 323-35.
7. Di Sebastiano P, di Mola FF, Bockman DE, Friess H, Buchler MW,. Chronic pancreatitis: The perspective of pain generation by neuroimmune interaction. Gut 2003; 52: 907-11.
8. Buscher HC, Wilder-Smith OH, van Goor H,. Chronic pancreatitis patients show hyperalgesia of central origin: A pilot study. Eur J Pain 2006; 10: 363-70.
9. Drewes AM, Gratkowski M, Sami SA, Dimcevski G, Funch-Jensen P, Arendt-Nielsen L,. Is the pain in chronic pancreatitis of neuropathic origin? Support from EEG studies during experimental pain. World J Gastroenterol 2008; 14: 4020-7.
10. Olesen SS, Brock C, Krarup AL, Funch-Jensen P, Arendt-Nielsen L, Wilder-Smith OH, Drewes AM,. Descending inhibitory pain modulation is impaired in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2010; 8: 724-30.
11. Edwards RR, Ness TJ, Weigent DA, Fillingim RB,. Individual differences in diffuse noxious inhibitory controls (DNIC): Association with clinical variables. Pain 2003; 106: 427-37.
12. de Vries M, van Rijckevorsel DC, Wilder-Smith OH, van Goor H,. Dronabinol and chronic pain: Importance of mechanistic considerations. Expert Opin Pharmacother 2014; 15: 1-10.
13. (R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012; 74: 42-53.
14. Munro S, Thomas KL, Abu-Shaar M,. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
15. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI,. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
16. Alexander SP, Mathie A, Peters JA,. Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 2011; 164 (Suppl 1): S1-324.
17. Hohmann AG, Herkenham M,. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett 1998; 252: 13-6.
18. Hohmann AG, Herkenham M,. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. Neuroscience 1999; 90: 923-31.
19. Hohmann AG, Briley EM, Herkenham M,. Pre- And postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25.
20. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN,. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9: 254-64.
21. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J,. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA 2015; 313: 2456-73.
22. Friedman H, Greenblatt DJ, Peters GR, Metzler CM, Charlton MD, Harmatz JS, Antal EJ, Sanborn EC, Francom SF,. Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992; 52: 139-50.
23. Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmoller J,. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther 2009; 85: 273-6.
24. Kirchheiner J, Brockmoller J,. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
25. Bond A, Lader M,. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47: 211-8.
26. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP,. Psychedelic effects of ketamine in healthy volunteers: Relationship to steady-state plasma concentrations. Anesthesiology 1998; 88: 82-8.
27. Lynch ME, Campbell F,. Cannabinoids for treatment of chronic non-cancer pain: A systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: 735-44.
28. Russo EB,. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008; 4: 245-59.
29. Beaulieu P, Ware M,. Reassessment of the role of cannabinoids in the management of pain. Curr Opin Anaesthesiol 2007; 20: 473-7.
30. Ben AM,. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006; 105: 1-25.
31. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C,. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia 2004; 59: 440-52.
32. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S,. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013; 260: 984-97.
33. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D,. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007; 133: 210-20.
34. Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM,. Effect of dronabinol on central neuropathic pain after spinal cord injury: A pilot study. Am J Phys Med Rehabil 2010; 89: 840-8.
35. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S,. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (sativex) in painful diabetic neuropathy: Depression is a major confounding factor. Diabetes Care 2010; 33: 128-30.
36. Svendsen KB, Jensen TS, Bach FW,. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253.
37. Berman JS, Symonds C, Birch R,. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004; 112: 299-306.
38. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS,. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50-2.
39. Rog DJ, Nurmikko TJ, Young CA,. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29: 2068-79.
40. Wade DT, Makela P, Robson P, House H, Bateman C,. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
41. Wade DT, Robson P, House H, Makela P, Aram J,. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17: 21-9.
42. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, Group UMR,. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
43. Cichewicz DL,. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-24.
44. Roberts JD, Gennings C, Shih M,. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530: 54-8.
45. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG,. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008; 109: 101-10.
46. Capurso G, Cocomello L, Benedetto U, Camma C, Delle FG,. Meta-analysis: The placebo rate of abdominal pain remission in clinical trials of chronic pancreatitis. Pancreas 2012; 41: 1125-31.
47. Lesko LJ,. Personalized medicine: Elusive dream or imminent Reality? Clin Pharmacol Ther 2007; 81: 807-16.
48. Bruehl S, Apkarian AV, Ballantyne JC, Berger A, Borsook D, Chen WG, Farrar JT, Haythornthwaite JA, Horn SD, Iadarola MJ, Inturrisi CE, Lao L, Mackey S, Mao J, Sawczuk A, Uhl GR, Witter J, Woolf CJ, Zubieta JK, Lin Y,. Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges. J Pain 2013; 14: 103-13.
49. Apkarian AV, Hashmi JA, Baliki MN,. Pain and the brain: Specificity and plasticity of the brain in clinical chronic pain. Pain 2011; 152: S49-64.
50. Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, Fields HL, Apkarian AV,. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci 2012; 15: 1117-9.
51. Woolf CJ,. Central sensitization: Implications for the diagnosis and treatment of pain. Pain 2011; 152: S2-15.
52. Forsmark CE,. Chronic pancreatitis and malabsorption. Am J Gastroenterol 2004; 99: 1355-7.
53. Pezzilli R,. Chronic pancreatitis: Maldigestion, intestinal ecology and intestinal inflammation. World J Gastroenterol 2009; 15: 1673-6.
54. Olesen AE, Brokjaer A, Fisher IW, Larsen IM,. Pharmacological challenges in chronic pancreatitis. World J Gastroenterol 2013; 19: 7302-7.
55. Pappagallo M,. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001; 182: 11S-8S.
56. Kaufmann RM, Kraft B, Frey R, Winkler D, Weiszenbichler S, Backer C, Kasper S, Kress HG,. Acute psychotropic effects of oral cannabis extract with a defined content of delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry 2009; 43: 24-32.
57. Enna SJ, McCarson KE,. The role of GABA in the mediation and perception of pain. Adv Pharmacol 2006; 54: 1-27.
58. Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU,. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 2009; 141: 233-8.
59. Vuilleumier PH, Besson M, Desmeules J, Arendt-Nielsen L, Curatolo M,. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain: A randomized placebo-controlled study. PLoS One 2013; 8: E43896.
60. Chapman CR, Feather BW,. Effects of diazepam on human pain tolerance and pain sensitivity. Psychosom Med 1973; 35: 330-40.